|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||1.9600 - 2.1100|
|52 Week Range||1.5400 - 6.7900|
|Beta (5Y Monthly)||1.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2022 - Mar 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
With the business potentially at an important milestone, we thought we'd take a closer look at Medexus Pharmaceuticals...
And medac, a strategic partner of Medexus, are pleased to announce that medac has resubmitted its New ...
Additional data collection and analysis reconfirms confidence in New Drug Application for TreosulfanNDA resubmission date consistent with previously announced timelineFDA decision still expected within six months of resubmission TORONTO and CHICAGO, April 22, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) and medac, a strategic partner of Medexus, are pleased to announce that medac has resubmitted its New Drug Application for Treosulfan (NDA) with the U.S. F